首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   28328篇
  免费   2415篇
  国内免费   1977篇
耳鼻咽喉   308篇
儿科学   242篇
妇产科学   278篇
基础医学   3134篇
口腔科学   356篇
临床医学   3523篇
内科学   3769篇
皮肤病学   238篇
神经病学   1518篇
特种医学   947篇
外国民族医学   9篇
外科学   3223篇
综合类   5593篇
现状与发展   4篇
预防医学   1838篇
眼科学   738篇
药学   3168篇
  27篇
中国医学   1689篇
肿瘤学   2118篇
  2025年   10篇
  2024年   292篇
  2023年   473篇
  2022年   1030篇
  2021年   1197篇
  2020年   990篇
  2019年   871篇
  2018年   793篇
  2017年   782篇
  2016年   756篇
  2015年   1169篇
  2014年   1381篇
  2013年   1417篇
  2012年   2182篇
  2011年   2020篇
  2010年   1500篇
  2009年   1232篇
  2008年   1460篇
  2007年   1540篇
  2006年   1554篇
  2005年   1492篇
  2004年   1183篇
  2003年   1280篇
  2002年   1094篇
  2001年   911篇
  2000年   791篇
  1999年   714篇
  1998年   354篇
  1997年   398篇
  1996年   282篇
  1995年   281篇
  1994年   222篇
  1993年   145篇
  1992年   163篇
  1991年   138篇
  1990年   142篇
  1989年   99篇
  1988年   83篇
  1987年   91篇
  1986年   58篇
  1985年   51篇
  1984年   24篇
  1983年   19篇
  1982年   9篇
  1981年   12篇
  1980年   4篇
  1979年   4篇
  1974年   5篇
  1972年   3篇
  1968年   3篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Background:Sacubitril/valsartan has been approved for the treatment of heart failure (HF) patients with reduced ejection fraction; since then, it gradually became a new star drug in the therapy of HF. Nevertheless, the effectiveness of sacubitril/valsartan remains under investigation. Thus far, only a few bibliometric studies have systematically analyzed the application of sacubitril/valsartan.Methods:Publications on sacubitril/valsartan were retrieved from the Web of Science Core Collection on April 29, 2021. Data were analyzed using Microsoft Excel 2019 (Redmond, WA), VOS viewer (Redmond, WA), and Cite Space V (Drexel University, Philadelphia, PA).Results:A total of 1309 publications on sacubitril/valsartan published from 1995 to 2021 were retrieved. The number of publications regarding sacubitril/valsartan increased sharply in the last 6 years (2015–2021), and American scholars authored >40% of those publications. Most were published in the European Journal of Heart Failure, the United States was the bellwether with a solid academic reputation in this area. Solomon published the highest number of related articles and was the most frequently cited author. “Heart failure” was the leading research hotspot. The keywords, “inflammation,” “fibrosis,” and “oxidative stress” appeared most recently as research fronts.Conclusions:Research attention should be focused on clinical trial outcomes. Considering its effectiveness in HF, the mechanisms and further applications of sacubitril/valsartan may become research hotspots in the future and should be closely examined.  相似文献   
102.
关节镜下缝线固定治疗儿童胫骨髁间前棘骨折   总被引:3,自引:1,他引:2  
目的探讨关节镜下应用缝线固定治疗儿童胫骨髁间前棘骨折的临床疗效。方法2003年5月~2006年7月,对11例胫骨髁间前棘骨折移位患儿,在关节镜下行骨折复位。以钢丝引导PDSⅡ缝线经骨隧道固定,术后石膏或支具外固定。术后随访采用IKDC和Lysholm评分标准评估疗效。结果全部病例均获随访,平均随访14个月(6~28个月),膝关节活动均正常,Lachman试验阴性;3~6个月,患儿均已恢复正常生活及部分体育锻炼;X线片显示骨折愈合。术后末次随访,KT-2000检查双膝松弛度相差0~4mm(平均1.5mm)。Lysholm评分术后末次随访93~100分,与术前56~79分比较,差异有统计学意义(P<0.01)。术后IKDC评分分级为A级(8例,占72.72%)和B级(3例,占27.28%)。结论儿童胫骨髁间前棘骨折经关节镜下骨折复位、缝线固定是一种创伤小、不损伤骺板、疗效可靠的治疗方法。  相似文献   
103.
目的:探讨三黄口服液对代谢综合征肥胖人群的临床疗效。方法:以20名健康志愿者为参照,将100名代谢综合征患者随机分为治疗组(60名)和安慰剂组(40名),分别予三黄口服液和安慰剂治疗12周,观察治疗前后患者心血管危险因素的变化。结果:与安慰剂组相比,治疗组(起效剂量为10 ml/人,黄连素浓度为0.16~0.22 mg/ml)除空腹血糖,甘油三酯在治疗前后无显著差异外,腰围、体质量指数、腰臀围比值、胰岛素抵抗指数,血清C反应蛋白水平、游离脂肪酸明显改善,差异有显著性(P<0.05);随着腰围的增大,男性的糖代谢异常、高血压病、血脂紊乱及代谢综合征的发生率均呈现增高趋势(P<0.01)。结论:三黄口服液可明显降低代谢综合征人群肥胖和胰岛素抵抗程度,并能改善炎症状态,减轻致心血管病的危险性。  相似文献   
104.
目的:通过系统综述总结我国2005-2012年发表文献使用的药源性肝损伤(DILI)的诊断标准,了解我国DILI诊断标准的使用情况及其特点.方法:中国期刊全文专题数据库(CNKI)、中国生物医学文献数据库(CBM)、维普中文科技期刊数据库(VIP)、万方数据以关键词“药物性/药源性+肝损害/肝损伤/肝病/肝炎”对2005-2012年文献进行检索,使用Noteexpress软件对检索到的文献进行管理,排除不同数据库间重复的文献,按照纳入和排除标准,对文献进行筛选.用Excel2007建立文献摘录表,进行数据提取和分析.结果:有273篇文献纳入研究,包括199篇病例系列和74篇病例报告.199篇病例系列采用的DILI诊断标准不一,有15个不同的标准,采用最多的是我国通用标准、1997年Maria评分、以及以“病史、临床表现和相关检查等”作为诊断标准.199篇病例系列对这3种标准的使用并没有明显随时间变化的趋势.不同类别杂志的文献对DILI诊断标准的使用也没有明显的趋势.74篇病例报告均是根据病史、临床表现和相关检查等做出诊断.结论:药源性肝损伤(DILI)目前没有统一的标准,在DILI诊断标准的选择上应根据患者年龄、原患疾病、临床症状、各项相关检查等选择合适的诊断标准,尽量避免漏诊和误诊的发生.  相似文献   
105.
106.
107.
OBJECTIVE: To analyze the levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in patients with benign and malignant ovarian tumors using a gold-standard assay and to investigate whether quantitative alterations of the circulating cell-free species have values in the management of the patients. METHODS: One hundred four patients were recruited for this study. We developed a quantitative, multiplex polymerase chain reaction to measure the levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in serum and plasma of patients with epithelial ovarian cancer, benign epithelial ovarian tumors, or endometriosis. The levels of the circulating cell-free DNA were compared with those of a healthy, age-matched control group. RESULTS: The patients with epithelial ovarian cancer had significantly higher amounts of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in plasma compared with the healthy control group (mean of nuclear DNA 10,723/2,591 and mean of mitochondrial DNA 4,918,978/2,294,264, P=.009 and 0.022, respectively) and with the other group with benign ovarian diseases (mean of nuclear DNA 10,723/2,965 and mean of mitochondrial DNA 4,918,978/1,597,551, P=.027 and 0.002, respectively). However, no relationship between levels of the circulating cell-free DNA and the pathological parameters as well as CA 125 measurement in patients with epithelial ovarian cancer was found. A significant difference between the epithelial ovarian cancer and endometriosis group was found in circulating cell-free mitochondrial DNA but not in circulating cell-free nuclear DNA (mean of mitochondrial DNA 4,918,978/2,273,988 and mean of nuclear DNA 10,723/3,291, P=.013 and 0.105, respectively). CONCLUSION: Elevated levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in epithelial ovarian cancer may have diagnostic value. Our finding suggests that the circulating molecules might be potential biomarkers in the disease.  相似文献   
108.
The clinical features of the maternal syndrome of pre-eclampsia can be explained by generalised maternal endothelial cell dysfunction, which is a part of a more global maternal systemic inflammatory response. There is growing evidence that these effects are associated with the shedding of cellular debris, including syncytiotrophoblast microparticles (STBM), cell-free DNA and mRNA, from the surface of the placenta (syncytiotrophoblast) into the maternal circulation. The increased shedding of this debris seen in pre-eclampsia is believed to be caused by placental ischaemia, reperfusion and oxidative stress. This study was carried out to determine whether uterine contractions during labour and subsequent placental separation lead to an acute increase in the release of placental debris into the maternal circulation. To assess the effects of labour, samples were taken from 10 normal pregnant (NP) and 10 pre-eclamptic (PE) women at varied time points. Similarly to assess the effects of placental delivery, plasma samples were taken from 10 NP and 10 PE women undergoing elective caesarean section. There was a significant increase in the shedding of STBM in pre-eclampsia which was not seen in normal pregnancy and there was a small rise in STBM levels at placental separation in both normal pregnant and pre-eclamptic women undergoing caesarean section, but the differences were not significant. However, levels of placental cell-free corticotrophin releasing hormone mRNA were significantly increased in labour in both normal pregnancy and pre-eclampsia and were still high 24 h after delivery in the pre-eclamptic women. There was no significant increase in fetal or total DNA in labour, but the overall levels of total DNA (maternal and fetal) was increased in labour in pre-eclampsia compared to normal labour. The enhanced shedding of STBM and CRH mRNA in pre-eclampsia labour may have a role in cases of postpartum worsening of pre-eclampsia.  相似文献   
109.
由中华医学会<中华妇产科杂志>编委会主办、南方医科大学南方医院协办的全国胎儿医学与产前诊断学术研讨会于2007年9月14-17日在花城广州召开.<中华妇产科杂志>总编辑郎景和教授、副总编辑黄醒华教授和林其德教授,以及来自全国各地近300名产科、新生儿科等专家和代表参加了会议.会议系统介绍了从早孕到分娩期多种现代产科胎儿疾病诊断、治疗和胎儿监测技术,围绕胎儿医学、遗传咨询、宫内诊断等临床热点进行了热烈讨论.会议特邀澳大利亚南澳洲大学副校长McMillen教授、中国香港中文大学刘子建教授、首都医科大学附属北京妇产医院黄醒华教授等17位国内外著名专家作了专题讲座,并先后有13位代表进行了大会论文报告.现将会议内容纪要如下.  相似文献   
110.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号